Peanut Allergy Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Peanut Allergy pipeline constitutes 15+ key companies continuously working towards developing 15+ Peanut Allergy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Peanut Allergy Overview
Peanut allergy accounts for the majority of severe food-related allergic reactions. It tends to present early in life, and affected individuals generally do not outgrow it.

"Peanut Allergy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peanut Allergy Market.

The Peanut Allergy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Peanut Allergy Pipeline Report: https://www.delveinsight.com/report-store/peanut-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Peanut Allergy treatment therapies with a considerable amount of success over the years. Peanut Allergy Key players such as - Allergy Therapeutics, Intrommune Therapeutics, InnoUp Farma, Cour Pharmaceutical, Vedanta Biosciences, Aravax, Prota Therapeutics, AstraZeneca, DBV technologies, Camallergy, Genentech, and others, are developing therapies for the Peanut Allergy treatment
• Peanut Allergy Emerging therapies such as - VLP Peanut, INT301, INP20, CNP-201, VE416, PVX-108, PRT100, Acalabrutinib, Viaskin Peanut, CA002, Omalizumab, and others are expected to have a significant impact on the Peanut Allergy market in the coming years.
• In June 2022, DBV Technologies announced positive topline results from Phase III EPITOPE Trial of Viaskin Peanut inPeanut-Allergic Toddlers
• In September 2022, the US Food and Drug Administration (FDA) has put a partial clinical hold on the phase III VITESSE(Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) clinical trial testing the efficacy and safety of epicutaneous immunotherapy with the modified Viaskin Peanut 250 µg patch in peanut-allergic children ages 4-7 year
• In December 2021, DBV Technologies announced that it has formally notified the European Medicines Agency (EMA) of its decision to withdraw the Marketing Authorization Application (MAA) for Viaskin Peanut

Route of Administration
Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Peanut Allergy Pipeline Therapeutics Assessment
• Peanut Allergy Assessment by Product Type
• Peanut Allergy By Stage and Product Type
• Peanut Allergy Assessment by Route of Administration
• Peanut Allergy By Stage and Route of Administration
• Peanut Allergy Assessment by Molecule Type
• Peanut Allergy by Stage and Molecule Type

DelveInsight's Peanut Allergy Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Peanut Allergy Therapeutics Market include:
Key companies developing therapies for Peanut Allergy are - Aimmune Therapeutics, Inc, Novartis Pharmaceuticals, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc, Vedanta Biosciences, Inc, Regeneron Pharmaceuticals, Genentech, Inc, Camallergy, Aravax, Inimmune, Prota therapeutics, Intrommune Therapeutics, Alladapt Immunotherapeutics, Siolta therapeutics, IgGenix and many others.

Emerging Peanut Allergy Drugs Under Different Phases of Clinical Development Include:
• VLP Peanut: Allergy Therapeutics
• INT301: Intrommune Therapeutics
• INP20: InnoUp Farma
• CNP-201: Cour Pharmaceutical
• VE416: Vedanta Biosciences
• PVX-108: Aravax
• PRT100: Prota Therapeutics
• Acalabrutinib: AstraZeneca
• Viaskin Peanut: DBV technologies
• CA002: Camallergy
• Omalizumab: Genentech

Get a Free Sample PDF Report to know more about Peanut Allergy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight

Peanut Allergy Pipeline Analysis:
The Peanut Allergy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Peanut Allergy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peanut Allergy Treatment.
• Peanut Allergy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peanut Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peanut Allergy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Peanut Allergy product details are provided in the report. Download the Peanut Allergy pipeline report to learn more about the emerging Peanut Allergy therapies at: https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Peanut Allergy Pipeline Market Drivers
• Increasing prevalence of peanut allergies
• Growth in commercial and scientific activities for research and development

Peanut Allergy Pipeline Market Barriers
• Lack of approved therapies
• Lack of public awareness of peanut allergy
• Accurate diagnosis of peanut allergy is critical.

Scope of Peanut Allergy Pipeline Drug Insight
• Coverage: Global
• Key Peanut Allergy Companies: Allergy Therapeutics, Intrommune Therapeutics, InnoUp Farma, Cour Pharmaceutical, Vedanta Biosciences, Aravax, Prota Therapeutics, AstraZeneca, DBV technologies, Camallergy, Genentech, and others
• Key Peanut Allergy Therapies: VLP Peanut, INT301, INP20, CNP-201, VE416, PVX-108, PRT100, Acalabrutinib, Viaskin Peanut, CA002, Omalizumab, and others
• Peanut Allergy Therapeutic Assessment: Peanut Allergy current marketed and Peanut Allergy emerging therapies
• Peanut Allergy Market Dynamics: Peanut Allergy market drivers and Peanut Allergy market barriers

Request for Sample PDF Report for Peanut Allergy Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Peanut Allergy Report Introduction
2 Peanut Allergy Executive Summary
3 Peanut Allergy Overview
4 Peanut Allergy- Analytical Perspective In-depth Commercial Assessment
5 Peanut Allergy Pipeline Therapeutics
6 Peanut Allergy Late Stage Products (Phase II/III)
7 Peanut Allergy Mid Stage Products (Phase II)
8 Peanut Allergy Early Stage Products (Phase I)
9 Peanut Allergy Preclinical Stage Products
10 Peanut Allergy Therapeutics Assessment
11 Peanut Allergy Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Peanut Allergy Key Companies
14 Peanut Allergy Key Products
15 Peanut Allergy Unmet Needs
16 Peanut Allergy Market Drivers and Barriers
17 Peanut Allergy Future Perspectives and Conclusion
18 Peanut Allergy Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Peanut Allergy drugs and therapies- https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Peanut Allergy Market https://www.delveinsight.com/report-store/peanut-allergy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Peanut Allergy-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Peanut Allergy Epidemiology https://www.delveinsight.com/report-store/peanut-allergy-pa-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Peanut Allergy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.